← All trials
NCT06306300
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 4, 2022
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Mar 12, 2024
- Last posted
- Mar 25, 2024
- Enrollment
- 30000
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Oswaldo Cruz FoundationLead sponsor
- Conselho Nacional de Desenvolvimento Científico e TecnológicoCollaborator
- Oswaldo Cruz FoundationSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.